Bill Querbes

Chief Scientific Officer Aera Therapeutics, Inc

Dr. Querbes is currently CSO at Aera. Prior to Aera, he served in several R&D roles including senior vice president of discovery and translational sciences at Tessera Therapeutics, vice president at AVROBIO and senior director at Synlogic, leading both research groups and development program teams. He spent 12 years at Alnylam Pharmaceuticals contributing to siRNA delivery platforms and the therapeutic pipeline. He led the discovery and early clinical development of GIVLAARI® (givosiran) for the treatment of hepatic porphyria, the first FDA approved GalNac conjugate RNAi therapeutic. He holds a B.S. from SUNY Geneseo and a Ph.D. from Brown University.

Seminars

Tuesday 15th September 2026
Optimizing In Vivo LNP Delivery of CAR mRNAs to Unlock Autoimmune Disease Treatments
2:30 pm
  • Optimizing LNP delivery systems for in vivo CAR-T 
  • Screening and selection of mRNA cargo 
  • Assembly of preclinical data package to support first in human studies
Bill Querbes - Aera Therapeutics - Expert Speaker at the 11th CAR-TCR Summit 2026